Forced-rate aerobic cycling enhances motor recovery in persons with chronic stroke: A

randomized clinical trial

Susan M. Linder, PT, DPT, PhD^{a,b}, Andrea Bischof-Bockbrader, BA, PTA^a, Sara Davidson, BS,

PTA^a, Yadi Li, MEd^c, Brittany Lapin, PhD^c, Tamanna Singh, MD^d, John Lee, MD^a, Francois

Bethoux, MD^a, Jay L. Alberts, PhD^b

^aCleveland Clinic, Department of Physical Medicine and Rehabilitation, Cleveland, OH, USA

^bCleveland Clinic, Department of Biomedical Engineering, Lerner Research Institute, Cleveland,

OH, USA

^cCleveland Clinic, Department of Quantitative Health Sciences, Lerner Research Institute,

Cleveland, OH, USA

dCleveland Clinic, Department of Cardiovascular Medicine; Heart, Vascular, and Thoracic

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

Institute, Cleveland, OH, USA

Corresponding author:

Susan M Linder, PT, DPT, PhD

linders@ccf.org

tel: 216-445-9815

fax: 216-636-2599

ABSTRACT

Background: The potential for intensive aerobic exercise to enhance neuroplasticity post-stroke has been theorized but not systematically investigated. Our aim was to determine the effects of forced-rate aerobic exercise paired with an abbreviated session of upper extremity (UE) repetitive task practice (FE+RTP) compared to time-matched UE repetitive task practice (RTP only) on the recovery of motor function in individuals with chronic stroke.

Methods: A single center randomized clinical trial was conducted from April 2019 to December

2022. Sixty individuals ≥6 months following single stroke with residual UE hemiparesis aged 18-85 were recruited. Participants were randomized 1:1 to one of two time-matched groups: FE+RTP (N=30) or RTP only (N=30). Both groups completed 90-minute sessions, 3x/week for 8 weeks. The FE+RTP group underwent 45-minutes of forced-rate aerobic exercise (FE) followed by 45-min of UE RTP. The RTP only group completed 2 sequential 45-minute sessions of UE RTP. The primary UE outcomes were the Fugl-Meyer Assessment (FMA) and the Action Research Arm Test (ARAT). The Six-minute Walk Test (6MWT) assessed walking capacity. **Results:** Sixty individuals $60.5 (\pm 10.6)$ years of age and 26.0 [13.0, 69.0] months post-stroke were enrolled, and 56 completed the study. The RTP only group completed more RTP in terms of repetitions (411.8±44.4 versus 222.8±28.4, P<0.001) and time (72.7±6.7 versus 37.8±2.4 minutes, P<0.001) compared to FE+RTP. Both groups improved on the FMA (FE+RTP, 36.2±10.1 to 44.0±11.8 and RTP only, 34.4±11.0 to 41.2±13.4, P<0.001) and ARAT (FE+RTP, 32.5±16.6 to 37.7±17.9 and RTP only, 32.8±18.6 to 36.4±18.5, P<0.001). A group main effect was not observed. The FE+RTP group demonstrated greater improvements on the 6MWT $(274.9\pm122.0 \text{ to } 327.1\pm141.2 \text{ meters})$ compared to the RTP only group $(285.5\pm160.3 \text{ to})$ 316.9±170.0, P=0.004).

Conclusions While both interventions elicited comparable improvements in UE motor recovery, the summative value of FE+RTP in improving UE and lower extremity function was demonstrated.

Trial Registration: ClinicalTrials.gov: NCT03819764

Introduction

Advances in the medical management of stroke have improved survival rates by nearly one-third over the past 20 years; however, disability rates post-stroke have not changed substantially. Despite extensive resources dedicated to rehabilitation, nearly two-thirds of survivors do not regain full use of their hemiparetic upper and lower extremities resulting in the inability to use the more affected hand, deficits in locomotion and mobility, and decreased community reintegration. Neuroplasticity, the ability of the central nervous system (CNS) to change in response to stimuli by strengthening existing and forming new neural connections, remains the tenet of motor recovery post-stroke. Notor learning-based therapies to drive the recovery of upper extremity (UE) function are considered the standard of care in post-stroke rehabilitation and include constraint-induced movement therapy and repetitive task practice (RTP). Clinical trials in the past two decades have focused on variations to these approaches of motor retraining therapies 1,10,11 and titrating the optimal dosage to drive neural recovery. However, the optimal method to facilitate UE motor recovery has not been determined and the causal relationship between dose and recovery remains unclear.

Principles of motor recovery indicate that neuroplasticity is experience-dependent, requiring motor task practice to improve function. Unfortunately, the dose of therapy most individuals post-stroke receive does not meet a level of practice necessary to realize the full recovery potential. There is emerging evidence to indicate that aerobic exercise (AE) improves brain function and promotes neuroplasticity. Studies in animals and humans indicate that AE can increase levels of brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1), neurotrophins thought to be key facilitators of neuroplasticity, implicated on a molecular level to encourage axonal and dendritic growth and remodeling,

synaptogenesis, and synaptic transmission efficacy.^{2,4,13,14,17,18} Numerous systematic reviews of animal and human literature have found that exercise intensity is an important factor in upregulating neurotrophins, with higher intensities eliciting greater responses compared to low-intensity AE approaches.^{13,14,16,17,19}

To harness the potential neuroplastic priming effects of AE, studies conducted in animals and neurologically healthy humans indicate that AE administered immediately prior to motor task practice enhances motor skill acquisition. ¹⁸ Our underlying hypothesis is that AE primes the CNS to facilitate neuroplasticity and its use in combination with motor task practice will optimize motor recovery. 4,13,15 To evaluate this hypothesis, we conducted successful preliminary studies suggesting AE training can enhance the motor learning benefits associated with UE RTP in individuals with stroke. 20,21 However, a barrier is that persons post-stroke often present with considerable declines in cardiovascular fitness and endurance, which necessarily limits the duration and intensity of AE. To overcome this deconditioning, we utilized a forced-rate exercise (FE) paradigm, an approach in which the voluntary efforts of participants are supplemented to facilitate exercise of greater intensity and duration to trigger potential neuroplastic benefits. During FE, pedaling cadence on a stationary cycle is supplemented by a motor to assist, but not replace, the voluntary efforts of the individual. We previously reported that when comparing FE to voluntary-rate exercise (VE), FE elicited greater improvements in motor recovery associated with UE RTP. 20,21

While our pilot studies demonstrated superiority of FE, the dose-response relationship with UE RTP was not evaluated. The aim of this project was to determine the effects of FE paired with an abbreviated session of UE RTP (FE+RTP) compared to time-matched UE RTP (RTP only) on the recovery of motor function in individuals with chronic stroke. We

hypothesized that FE+RTP would yield greater improvements in UE motor recovery compared to time-matched RTP only.

Materials and Methods

A single-center, parallel group, rater blinded randomized clinical trial with a 1:1 allocation ratio was conducted at the Cleveland Clinic between April 2019 and December 2022. The trial was funded by the National Institutes of Health (K01HD092556), registered prospectively at ClinicalTrials.gov (NCT03819764) and conducted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines.

Participants and Screening

Sixty individuals were recruited via a stroke research participant registry, clinician outreach, and support group education sessions. Inclusion criteria were: 1) ≥6 months since a single ischemic or hemorrhagic stroke; 2) UE Fugl-Meyer motor score 19-55; 3) ambulatory ≥20 meters with no more than contact guard assistance; and 4) 18-85 years of age. Exclusion criteria were: 1) hospitalization for myocardial infarction, heart failure or heart surgery within 3 months, 2) cardiac arrhythmia, 3) hypertrophic cardiomyopathy, 4) severe aortic stenosis, 5) pulmonary embolus, 6) significant contractures, 7) anti-spasticity injection to paretic UE within 3 months of enrollment and 8) other contraindications to exercise. The study was approved by the Cleveland Clinic Institutional Review Board and the informed consent process was completed with all participants.

After meeting initial screening criteria, ²² participants underwent cardiopulmonary exercise (CPX) testing administered by an exercise physiologist at baseline and end of treatment (EOT) to determine baseline function and cardiopulmonary response to maximum exertion.

Participants completed testing while on all prescribed medications to obtain an accurate measure

of heart rate (HR) and blood pressure response. A 12-lead electrocardiogram was assessed prior to exercise and monitored continuously throughout exercise and recovery. An individualized ramp protocol was employed on an electronically controlled Lode cycle ergometer (Lode, Groningen, The Netherlands) using MedGraphics CardioO2/CP system (MCG Diagnostics, St. Paul, MN) with the ramp set to elicit a test duration of approximately 10 minutes. Participants were encouraged to exercise until volitional fatigue or standard test termination criteria according to the American College of Sports Medicine (ACSM) Guidelines for Exercise Testing and Prescription.²³ Results were interpreted by the study cardiologist to determine participant safety.

Outcomes

Clinical outcomes evaluating UE motor recovery and walking capacity were obtained at baseline, EOT, and 4 weeks following EOT (EOT+4) by the same trained physical therapist blinded to group allocation. The primary impairment-based motor outcome was the UE Fugl-Meyer Assessment (FMA)²⁴, which evaluates the ability of the individual to move out of synergistic patterns toward isolated movement control.²⁵ The primary functional-based motor outcome was the Action Research Arm Test (ARAT),²⁶ which includes 19 tests of fine and gross motor function, grouped in categories of grasp, grip, pinch and gross movement. The Wolf Motor Function Test (WMFT) served as secondary motor outcome.²⁷

The six-minute walk test (6MWT) was administered along a continuous 100-meter oval lap as a measure of walking capacity. Participants used assistive devices and orthoses as prescribed for community ambulation, with equipment remaining consistent across testing time points.

Interventions

Following baseline testing, participants (N=60) underwent concealed randomization stratified by baseline UE FMA level (≤33 or >33) using a nonreplenished sealed opaque envelope pull method to one of two time-matched groups: 1) forced-rate aerobic exercise and repetitive task practice (FE+RTP, N=30) or 2) RTP only (N=30). Randomization was conducted by the research therapist who was not involved in the collection of outcomes. Participants in both groups completed 24 visits, 3x per week for 8 weeks, and were permitted up to 12 weeks to complete the 24 visits to allow for vacations, illness, or holidays. Study visits for both groups were matched at 90 minutes in length.

Forced Exercise + Repetitive Task Practice: Participants in the FE+RTP group completed a 45minute session of supervised AE on a custom-engineered motor-assisted stationary semirecumbent cycle ergometer, followed by 45-minutes of UE RTP. Participants were instructed to exercise within their target HR zone during the 35-minute main exercise set, which occurred between a 5-minute warm-up and 5-minute cool-down. Target HR range was individualized using the Karvonen formula at 60-80% of maximum HR based on CPX testing.²⁸ Heart rate was monitored and recorded continuously using a Wahoo chest strap (Wahoo Fitness, Atlanta, GA), synced and displayed continuously on an Apple iPad (Apple, Inc, Cupertino, CA), allowing the therapist and participant to monitor aerobic intensity, facilitating adherence to prescribed values. Participants were instructed to actively pedal with the motor to achieve target HR response. Cycling cadence was programmed by the therapist based on the individual's ability to contribute to the workload with a target cadence of \geq 75 revolutions per minute (RPM), based on results from previous studies indicating better outcomes at higher cycling cadence.²⁰ Average HR during the warm-up, main set, and cool down were recorded. Blood pressure and rating of perceived exertion were recorded every 10 minutes. Training was conducted under the

supervision of a physical therapist or physical therapist assistant certified in Basic Life Support.

Participants completed a 45-minute session of UE RTP immediately following their FE session.

Repetitive task practice

Repetitive task practice emphasizes highly repetitious UE tasks that are functional, goaloriented and relevant to the individual, administered using blocked practice. The RTP approach
was identical to our previous studies, ^{20,21} originally modeled after Birkenmeier and
colleagues. ^{6,8,29} Tasks were individualized to each participant's goals and abilities and included
gross and fine motor components involving proximal and distal motor control; for example,
reaching to a shelf positioned at knee height, grasping a plastic cup, and placing it onto a shelf
positioned at shoulder height. The RTP activities were administered by a licensed neurologic
physical therapist or physical therapist assistant who tailored each task to ensure appropriate
difficulty. During a 45-minute RTP session, participants completed 3-5 tasks, targeting 60-90
repetitions of each task. Time spent completing tasks and number of repetitions were recorded.
The RTP intervention was administered in the same manner for both groups; however, to ensure
a time-matched intervention, the FE+RTP group participated in a 45-min session immediately
after 45-min of FE, while the RTP only group completed two sequential 45-min RTP sessions.

Statistical Analysis

The power and sample size calculation was based on FMA scores from our pilot study.²¹ Assuming a minimal clinically important difference (MCID) value for the UE FMA of 4.25 points³⁰ and an increase of 2*MCID for the FE+RTP group and 1*MCID for the RTP only group, an n=30 in group provided a .87 power at the 0.05 significance level to detect pairwise group differences equivalent to an effect size of .4.

Intention to treat analysis was conducted. Participant demographics, clinical characteristics, intervention parameters, and outcomes were summarized by mean with standard deviation or median with interquartile range for continuous variables, and count with percentage for categorical variables.

Mixed-effects models were used to model outcomes over time. Outcomes at baseline, EOT and EOT+4 were dependent variables. Independent variables include time point (baseline, EOT and EOT+4), group, and interaction between time and group. Subject random effect was included in the model. Interaction term was excluded if it was non-significant (p>0.05).

A responder analysis was conducted by determining the number of participants with change scores that exceed the MCID from baseline to EOT and EOT+4, for FMA, ARAT, and 6MWT. The distribution of responses for both groups were graphed using a cumulative distribution function.³¹

Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc, Cary, NC) with statistical significance established throughout at p<0.05.

Results

Sixty participants met participation criteria, were consented, and enrolled. Participants were 60.5 (± 10.6) years of age and 58.3% male. Racial distribution included 78.3% white, 20.0% Black/African American, and 1.7% Asian. Median time since stroke was 26.0 [13.0, 69.0] months. Detailed demographics, which were similar across groups, are presented in Table 1. Both interventions were well-tolerated by participants, with an overall retention of 93.3% and no serious adverse events related to study interventions. Twenty-nine participants in the FE+RTP group and 27 in the RTP only group completed the intervention and EOT testing. Two FE+RTP participants impacted by the mandatory Covid 19 shutdown completed 20 and 21 sessions rather

than the planned 24 sessions. The study team conducted EOT testing immediately prior to the shutdown to preserve outcomes from their participation. Two additional participants randomized to FE+RTP completed only 2 and 6 sessions prior to the shutdown. Both resumed the intervention 12 weeks later, restarting with session one. The CONSORT flow diagram is shown in Figure 1.

Intervention Variables

Average FE session duration was 44.8 (\pm 0.35) minutes, aerobic intensity was 56.4 (\pm 12.1) percent of heart rate reserve (HRR), power output was 46.5 (\pm 42.7) watts, and cycling cadence was 74.3 (\pm 7.3) RPM (Table 1). As expected, those in the RTP only group, compared to the FE+RTP group, completed nearly twice the repetitions of RTP, (411.8 \pm 44.4 versus 222.8 \pm 28.4, P<0.001) and spent more time completing RTP (72.7 \pm 6.7 versus 37.8 \pm 2.4 minutes, P<0.001).

Upper Extremity Motor Outcomes

Significant improvements in UE motor recovery (Table 2) were measured for both groups from baseline to EOT in the UE FMA, (FE+RTP, 36.2 ± 10.1 to 44.0 ± 11.8 and RTP only, 34.4 ± 11.0 to 41.2 ± 13.4 , P<0.001) and the ARAT (FE+RTP, 32.5 ± 16.6 to 37.7 ± 17.9 and RTP only, 32.8 ± 18.6 to 36.4 ± 18.5 , P<0.001). A group main effect was not present for any UE outcomes (Figure 3a-b).

Walking Capacity and Cardiovascular Fitness

As hypothesized, the FE+RTP group demonstrated significantly greater improvements in the 6MWT (274.9 \pm 122.0 to 327.1 \pm 141.2 meters) compared to the RTP only group (285.5 \pm 160.3 to 316.9 \pm 170.0, P=0.004, Table 2, Figure 3c) and aerobic capacity measured by peak

oxygen consumption (FE+RTP, 16.6 ± 5.3 to 18.3 ± 6.4 versus RTP only, 16.3 ± 5.5 to 17.2 ± 5.6 mL/kg/min, P=0.024, Table 2).

Responder Analysis

Change scores for the FMA, ARAT, and 6MWT that exceeded the respective MCIDs are shown in Table 3 and Figure 2. More participants in the FE+RTP group exceeded MCID thresholds at EOT and EOT+4 for all outcomes, with the exception of FMA ≥7.25 at EOT+4. Significantly more FE+RTP participants exceeded MCID on the 6MWT at EOT and EOT+4 than the RTP only group.

Discussion

An intervention comprised of AE and RTP produced similar improvements in UE motor performance as an RTP intervention that was twice as long. Similar motor response with half the RTP dose suggests that AE may be priming the CNS to optimize neuroplasticity in persons with stroke and should be considered as an adjunct to traditional RTP. Unique to the FE+RTP group, significant and clinically meaningful improvements in locomotion and cardiovascular fitness were elicited. In sum, the FE+RTP group demonstrated greater overall gains in functional recovery than the RTP only group.

Recommendations for individuals post-stroke to engage in AE are not new; however, the benefits for CNS function have historically not been emphasized.³² Sustained and intensive AE has been shown to elicit vascular and neurochemical responses within the CNS, hypothesized as the mechanism by which AE facilitates neuroplasticity^{4,15,16,33-36}. Based on these data, our scientific premise was that intensive AE administered through FE would prime the CNS and optimize recovery associated with motor task practice. We used FE to supplement the voluntary efforts of participants to overcome barriers to completing high intensity AE that individuals post-

stroke experience, including hemiparesis, fatigue, spasticity, impaired balance, and reduced cardiovascular fitness.³⁷ Participants in the FE+RTP group exercised for 45 minutes at an aerobic intensity (56.4 percent of HRR) that is nearly equivalent to ACSM exercise guidelines for the general population.³⁸ Therefore, supplementing the individuals' voluntary efforts using FE facilitated a relatively intensive exercise duration (i.e.: 45 minutes/session) without compromising aerobic intensity.

Because FE involved lower limb cycling, it was unlikely to elicit a transfer of training effect to impact UE function; thus, we hypothesize that a global priming effect was induced, enhancing UE recovery. The MCID for the FMA ranges from 4.25 to 7.25 points.³⁰ Despite half the RTP dosage, mean change scores for the FE+RTP group exceeded the upper value of MCID range for the FMA at both time points and responder analyses (Table 3) reveal that more participants in the FE+RTP group exceeded the MCID for the ARAT at both time points. In a previous study investigating RTP dosage, Lang and colleagues reported change in ARAT scores of 5.8 and 5.1 for participants receiving 13.6 and 20 hours of UE RTP, respectively, while our FE+RTP group demonstrated a 5.3 point change after 18 hours of RTP. By comparison, the RTP only group receiving a total of 36 hours of RTP improved by 3.8 points. We acknowledge that a gap is the investigation of mechanisms that may be responsible for the improvements observed. Future studies have been proposed that include neural and biochemical mechanisms that underlie exercise-induced plasticity.

While not designed to improve walking, a significant and meaningful by-product of FE+RTP was improvements in walking capacity, with a change in 6MWT distance of 52.2 meters, exceeding the MCID of 34.4 meters.³⁹ These results approach the robust improvements in 6MWT values recently reported by Boyne and colleagues after 8 weeks of high-intensity

interval treadmill-based gait training administered 3x/week⁴⁰ and suggest that FE improves locomotor function, dispelling an assumption that cycling provides limited transfer of training to walking. 41 An interim analysis of data from the FE+RTP group revealed normalization of gait kinematics and kinetics associated with increased gait velocity following FE, indicating participants improved locomotor control and did not exaggerate existing compensatory strategies to walk faster. 42 Task-specificity, a fundamental concept in motor learning, has long been considered critical for neuroplasticity; yet our FE+RTP intervention did not involve task-specific gait training. While cycling and walking are different tasks, improvements in LE kinematics and kinetics from cycling may transfer to gait, as both require the rapid reciprocal activation and relaxation of lower extremity muscles synergistically, and some have proposed similar controlling neural networks. 43-46 Pedaling data from our pilot study revealed increased hemiparetic limb torque production, improved symmetry of force production, and diminished roughness index (a measure of motion smoothness) as a result of cycling. 47,48 Increased somatosensory input, muscle power, lower limb motor control, and/or endurance may have elicited these gains. 49,50

Conclusions and Future Directions

Our findings that an aerobic cycling intervention administered immediately prior to UE RTP can elicit robust improvements in UE function and locomotion comparable to task-specific training approaches can have significant implications on clinical practice. The FE+RTP intervention was tolerated by all participants without serious adverse events and its summative value in improving UE, lower extremity, and cardiovascular outcomes was demonstrated. Future studies employing mechanistic and clinical outcomes to elucidate the role of AE in eliciting a global response in the CNS and facilitating neuroplasticity are warranted.

Acknowledgements: The authors acknowledge Anson Rosenfeldt, DPT, and Cindy Clark, OT for administering study-related interventions.

Disclosures: Dr. Alberts has authored intellectual property protecting the forced-rate exercise cycle algorithm.

REFERENCES:

- 1. Winstein CJ, Stein J, Arena R, et al. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation. 2016;47(6):e98-e169.
- 2. Dobkin BH. Clinical practice. Rehabilitation after stroke. *The New England journal of medicine*. 2005;352(16):1677-1684.
- 3. Duncan PW, Sullivan KJ, Behrman AL, et al. Body-weight-supported treadmill rehabilitation after stroke. *N Engl J Med*. 2011;364(21):2026-2036.
- 4. Mang CS, Campbell KL, Ross CJ, Boyd LA. Promoting neuroplasticity for motor rehabilitation after stroke: considering the effects of aerobic exercise and genetic variation on brain-derived neurotrophic factor. *Physical therapy*. 2013;93(12):1707-1716.
- 5. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. *The Lancet.* 2011;377(9778):1693-1702.
- 6. Birkenmeier RL, Prager EM, Lang CE. Translating animal doses of task-specific training to people with chronic stroke in 1-hour therapy sessions: a proof-of-concept study. *Neurorehabilitation and neural repair*. 2010;24(7):620-635.
- 7. Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. *JAMA*. 2006;296(17):2095-2104.
- 8. Lang CE, Strube MJ, Bland MD, et al. Dose response of task-specific upper limb training in people at least 6 months poststroke: A phase II, single-blind, randomized, controlled trial. *Ann Neurol*. 2016;80(3):342-354.
- 9. Winstein CJ, Wolf SL, Dromerick AW, et al. Effect of a Task-Oriented Rehabilitation Program on Upper Extremity Recovery Following Motor Stroke: The ICARE Randomized Clinical Trial. *JAMA*. 2016;315(6):571-581.
- 10. Winstein CJ, Wolf SL, Dromerick AW, et al. Interdisciplinary Comprehensive Arm Rehabilitation Evaluation (ICARE): a randomized controlled trial protocol. *BMC Neurol.* 2013;13:5.
- 11. Page SJ, Levine P, Leonard A, Szaflarski JP, Kissela BM. Modified constraint-induced therapy in chronic stroke: results of a single-blinded randomized controlled trial. *Physical therapy*. 2008;88(3):333-340.
- 12. Lang CE, Lohse KR, Birkenmeier RL. Dose and timing in neurorehabilitation: prescribing motor therapy after stroke. *Curr Opin Neurol.* 2015;28(6):549-555.
- 13. Ploughman M, Austin MW, Glynn L, Corbett D. The effects of poststroke aerobic exercise on neuroplasticity: a systematic review of animal and clinical studies. *Transl Stroke Res.* 2015;6(1):13-28.
- 14. Ploughman M, Kelly LP. Four birds with one stone? Reparative, neuroplastic, cardiorespiratory, and metabolic benefits of aerobic exercise poststroke. *Curr Opin Neurol.* 2016;29(6):684-692.
- 15. Ploughman M, McCarthy J, Bosse M, Sullivan HJ, Corbett D. Does treadmill exercise improve performance of cognitive or upper-extremity tasks in people with chronic stroke? A randomized cross-over trial. *Archives of physical medicine and rehabilitation*. 2008;89(11):2041-2047.
- 16. Knaepen K, Goekint M, Heyman EM, R. M. Neuroplasticity Exercise-induced response of peripheral brain-derived neurotrophic factor. *Sports medicine*. 2010;40(9):765-801.
- 17. Boyne P, Meyrose C, Westover J, et al. Exercise intensity affects acute neurotrophic and neurophysiological responses poststroke. *J Appl Physiol* (1985). 2019;126(2):431-443.
- 18. Statton MA, Encarnacion M, Celnik P, Bastian AJ. A Single Bout of Moderate Aerobic Exercise Improves Motor Skill Acquisition. *PloS one*. 2015;10(10):e0141393.

- 19. Zhou B, Wang Z, Zhu L, et al. Effects of different physical activities on brain-derived neurotrophic factor: A systematic review and bayesian network meta-analysis. *Front Aging Neurosci*. 2022:14:981002.
- 20. Linder SM, Rosenfeldt AB, Davidson S, et al. Forced, Not Voluntary, Aerobic Exercise Enhances Motor Recovery in Persons With Chronic Stroke. *Neurorehabilitation and neural repair*. 2019;33(8):681-690.
- 21. Linder SM, Rosenfeldt AB, Dey T, Alberts JL. Forced Aerobic Exercise Preceding Task Practice Improves Motor Recovery Poststroke. *The American journal of occupational therapy*. 2017;71(2):7102290020p7102290021-7102290020p7102290029.
- 22. Riebe D, Franklin BA, Thompson PD, et al. Updating ACSM's Recommendations for Exercise Preparticipation Health Screening. *Medicine and science in sports and exercise*. 2015;47(11):2473-2479.
- 23. American College of Sports Medicine. *ACSM's resource manual for guidelines for exercise testing and prescription.* 7th ed. Philadelphia: Wolters Kluwer and Lippincott Williams & Wilkins; 2014.
- 24. Sullivan KJ, Tilson JK, Cen SY, et al. Fugl-Meyer assessment of sensorimotor function after stroke: standardized training procedure for clinical practice and clinical trials. *Stroke; a journal of cerebral circulation*. 2011;42(2):427-432.
- 25. Gladstone DJ, Danells CJ, Black SE. The fugl-meyer assessment of motor recovery after stroke: a critical review of its measurement properties. *Neurorehabil Neural Repair*. 2002;16(3):232-240.
- 26. Lang CE, Wagner JM, Dromerick AW, Edwards DF. Measurement of upper-extremity function early after stroke: properties of the action research arm test. *Archives of physical medicine and rehabilitation*. 2006;87(12):1605-1610.
- 27. Wolf SL, Catlin PA, Ellis M, Archer AL, Morgan B, Piacentino A. Assessing Wolf motor function test as outcome measure for research in patients after stroke. *Stroke; a journal of cerebral circulation*. 2001;32(7):1635-1639.
- 28. Ignaszewski M, Lau B, Wong S, Isserow S. The science of exercise prescription: Martti Karvonen and his contributions. *BC Medical Journal*. 2017;59(1):38-41.
- 29. Lang CE, Birkenmeier RL. *Upper-Extremity Task-Specific Training After Stroke or Disability.* Bethesda, MD: AOTA Press; 2014.
- 30. Page SJ, Fulk GD, Boyne P. Clinically important differences for the upper-extremity Fugl-Meyer Scale in people with minimal to moderate impairment due to chronic stroke. *Physical therapy*. 2012;92(6):791-798.
- 31. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. *Expert Rev Pharmacoecon Outcomes Res.* 2011;11(2):163-169.
- 32. Billinger SA, Arena R, Bernhardt J, et al. Physical Activity and Exercise Recommendations for Stroke Survivors: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation. 2014.
- 33. Pereira ED, Viana CS, Taunay TC, Sales PU, Lima JW, Holanda MA. Improvement of cognitive function after a three-month pulmonary rehabilitation program for COPD patients. *Lung*. 2011;189(4):279-285.
- 34. Kinni H, Guo M, Ding JY, et al. Cerebral metabolism after forced or voluntary physical exercise. *Brain research.* 2011;1388:48-55.
- 35. Hirsch M, Farley B. Exercise and neuroplasticity in persons living with Parkinson's disease. *European Journal of Physical and Rehabilitation Medicine*. 2009;45(2):215-229.
- 36. Voss MW, Prakash RS, Erickson KI, et al. Plasticity of brain networks in a randomized intervention trial of exercise training in older adults. *Front Aging Neurosci.* 2010;2.

- 37. Fini NA, Bernhardt J, Said CM, Billinger SA. How to Address Physical Activity Participation After Stroke in Research and Clinical Practice. *Stroke; a journal of cerebral circulation*. 2021:52(6):e274-e277.
- 38. Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Medicine and science in sports and exercise*. 2011;43(7):1334-1359.
- 39. Tang A, Eng JJ, Rand D. Relationship between perceived and measured changes in walking after stroke. *Journal of neurologic physical therapy : JNPT.* 2012;36(3):115-121.
- 40. Boyne P, Billinger SA, Reisman DS, et al. Optimal Intensity and Duration of Walking Rehabilitation in Patients With Chronic Stroke: A Randomized Clinical Trial. *JAMA Neurol.* 2023;80(4):342-351.
- 41. Hornby TG, Reisman DS, Ward IG, et al. Clinical Practice Guideline to Improve Locomotor Function Following Chronic Stroke, Incomplete Spinal Cord Injury, and Brain Injury. *Journal of neurologic physical therapy : JNPT.* 2020;44(1):49-100.
- 42. Linder SM, Learman K, Miller Koop M, et al. Increased comfortable gait speed is associated with improved gait biomechanics in persons with chronic stroke completing an 8-week forced-rate aerobic cycling intervention: a preliminary study. *Am J Phys Med Rehabil*. 2023.
- 43. Brown DA, Kukulka CG. Human flexor reflex modulation during cycling. *Journal of neurophysiology*. 1993;69(4):1212-1224.
- 44. Raasch CC, Zajac FE. Locomotor strategy for pedaling: muscle groups and biomechanical functions. *Journal of neurophysiology*. 1999;82(2):515-525.
- 45. Kautz SA, Brown DA. Relationships between timing of muscle excitation and impaired motor performance during cyclical lower extremity movement in post-stroke hemiplegia. *Brain : a journal of neurology.* 1998;121 (Pt 3):515-526.
- 46. Chen HY, Chen SC, Chen JJ, Fu LL, Wang YL. Kinesiological and kinematical analysis for stroke subjects with asymmetrical cycling movement patterns. *J Electromyogr Kinesiol*. 2005;15(6):587-595.
- 47. Linder SM, Rosenfeldt AB, Bazyk AS, Koop MM, Ozinga S, Alberts JL. Improved lower extremity pedaling mechanics in individuals with stroke under maximal workloads. *Top Stroke Rehabil*. 2018;25(4):248-255.
- 48. Chakraborty S, Dey T, Mukherjee A, Alberts JL, Linder SM. Functional modeling of pedaling kinematics for the Stroke patients. *J Biopharm Stat.* 2020;30(4):674-688.
- 49. Lee MJ, Kilbreath SL, Singh MF, et al. Comparison of effect of aerobic cycle training and progressive resistance training on walking ability after stroke: a randomized sham exercise-controlled study. *J Am Geriatr Soc.* 2008;56(6):976-985.
- 50. Yang HC, Lee CL, Lin R, et al. Effect of biofeedback cycling training on functional recovery and walking ability of lower extremity in patients with stroke. *The Kaohsiung journal of medical sciences*. 2014;30(1):35-42.

Figure Legends:

Figure 1. CONSORT Flow Diagram. Abbreviations: FE+RTP, forced-rate exercise plus repetitive task practice; RTP only, repetitive task practice only; AEs, adverse events; EOT, end of treatment; EOT+4, 4 weeks following end of treatment

Figure 2. Cumulative distribution function of change for outcomes from baseline to EOT Change scores for the Upper Extremity Fugl-Meyer Motor score (FMA, 2a), Action Research Arm Test (ARAT, 2b), and Six-minute walk test (6MWT, 2c) are shown with the minimal clinically important difference (MCID) range or value depicted by the blue horizontal shading or line, respectively. The y-axis shows the proportion of patients at each point along the outcome scale (x-axis) who experience change at that point or lower. While both groups made statistically significant improvement on the FMA and ARAT, more participants in the FE+RTP group exceeded MCID thresholds at EOT.

Figure 3. Violin dot plots depicting change scores from baseline to end of treatment (EOT, left panel) and baseline to EOT+4 weeks (right panel) with each dot representing a participant.

Change scores for the Upper Extremity Fugl-Meyer Motor score (FMA, 3a), Action Research Arm Test (ARAT, 3b), and Six-minute walk test (6MWT, 3c) are shown with the minimal clinically important difference (MCID) range or value depicted by the blue horizontal shading or line, respectively. While both groups made significant improvement on the FMA and ARAT, more participants in the FE+RTP group exceeded MCID thresholds at all time points with the exception of FMA ≥7.25 at EOT+4. With respect to change in walking capacity measured by the 6MWT, only the FE+RTP group made significant improvements at both time points with group means exceeding MCID.

Table 1. Demographics, clinical characteristics, and intervention parameters of the study sample, stratified by groups

	FE+RTP	RTP+RTP	
	(N=30)	(N=30)	
Age	60.8 ± 11.5	60.2 ± 9.8	
Sex			
Male	18 (60.0)	17 (56.7)	
Female	12 (40.0)	13 (43.3)	
Race			
White	23 (76.7)	24 (80.0)	
African American	7 (23.3)	5 (16.7)	
Asian	0 (0.00)	1 (3.3)	
Stroke Type			
Ischemic	24 (80.0)	23 (76.7)	
Hemorrhagic	6 (20.0)	7 (23.3)	
Dominant side affected			
Yes	15 (50.0)	14 (46.7)	
No	15 (50.0)	16 (53.3)	
Side affected			
Left	15 (50.0)	13 (43.3)	
Right	15 (50.0)	17 (56.7)	
Time since stroke (months)	18.5 [9.5, 60.0]	36.0 [14.0, 72.0]	
Co-Morbidities			
Hypertension	19 (63.3)	19 (63.3)	
Hyperlipidemia	20 (66.7)	22 (73.3)	
Diabetes	9 (30.0)	9 (30.0)	
History of myocardial infarction	1 (3.0)	1 (3.0)	
Prescribed Medication Usage			
Anti-hypertensive			
Any	20 (66.7)	19 (63.3)	
Beta-blocker	10 (33.3)	11 (36.7)	

Statin	21 (70.0)	19 (63.3)	
Anti-spasticity medication	6 (20.0)	7 (23.3)	
Anti-depressant	12 (40.0)	11 (36.7)	
Anti-coagulant	21 (70.0)	16 (53.3)	
Diuretic	3 (10.0)	6 (20.0)	
Diabetes medication	7 (23.3)	9 (30.0)	
Anti-seizure medication	6 (20.0)	3 (10.0)	
Pain medication	5 (16.7)	5 (16.7)	
Baseline Function			
Fugl-Meyer (UE motor score out of 66)	36.2 ± 10.1	34.4 ± 11.0	
Action Research Arm Test			
Total Score	32.5 ± 16.6	32.8 ± 18.6	
Grasp Subscale	11.2 ± 5.7	11.4 ± 6.8	
Grip Subscale	6.8 ± 3.1	6.0 ± 3.9	
Pinch Subscale	8.0 ± 6.6	8.5 ± 7.0	
Gross Subscale	6.5 ± 2.3	6.9 ± 2.3	
Wolf Motor Function Test			
Log performance time	2.4 ± 1.1	2.7 ± 1.2	
geometric mean (SD)	11.0 (3.0)	14.9 (3.3)	
Functional ability score	2.7 ± 1.3	2.7 ± 1.5	
Number of incomplete tasks in 120 s	1.5 ± 2.6	2.4 ± 3.2	
Grip strength, kg	13.8 ± 7.9	13.8 ± 8.9	
Weight to box, pounds	8.2 ± 6.3	8.7 ± 7.2	
Six-minute walk test distance, m	274.9 ± 122.0	285.5 ± 160.3	
Peak VO ₂ , mL/kg/min	16.6 ± 5.3	16.3 ± 5.5	
Intervention Variables			p-value
Aerobic intensity			
(% of heart rate reserve)	56.4 ± 12.1		
Pedaling cadence (revolutions per minute)	74.3 ± 7.3		

Duration of exercise session, min	44.8 ± 0.35		
Power (watts)	46.5 ± 42.7		
Time spent completing RTP per session, min	37.8 ± 2.4	72.7 ± 6.7	<0.001
Number of repetitions of RTP completed per session	222.8 ± 28.4	411.8 ± 44.4	<0.001
Number of tasks practiced per session	4.9 ± 0.49	8.0 ± 0.62	<0.001

Statistics presented as Mean ± SD, Median [P25, P75], N (column %); p-values from Satterthwaite t-test

Abbreviations: FE+RTP, forced-rate exercise plus repetitive task practice; RTP only, repetitive task practice only; UE, upper extremity; VO₂, volume of oxygen consumption; RTP, repetitive task practice

Table 2. Changes from Baseline to EOT and EOT+4 by Group

	EOT		EO1	EOT + 4		
	FE+RTP	RTP only	FE+RTP	RTP only	Group P-Value	Time P-Value
Fugl-Meyer (UE motor score) †	7.8 ± 4.0	6.6 ± 4.9	8.4 ± 4.5	8.2 ± 5.8	0.44	<0.001
Action Research Arm Test						
Total Score [†]	5.3 ± 6.0	3.8 ± 6.0	5.8 ± 5.9	4.4 ± 6.4	0.88	<0.001
Grasp Subscale †	1.9 ± 2.5	1.2 ± 2.9	2.2 ± 2.5	1.5 ± 2.9	0.89	<0.001
Grip Subscale [†]	0.76 ± 1.6	0.89 ± 1.3	0.81 ± 1.5	1.00 ± 1.6	0.46	<0.001
Pinch Subscale †	1.9 ± 2.7	1.2 ± 3.3	1.9 ± 2.8	1.6 ± 3.7	0.96	<0.001
Gross Subscale †	0.76 ± 1.3	0.48 ± 0.89	0.96 ± 1.3	0.38 ± 1.2	0.81	<0.001
Wolf Motor Function Test						
Log performance time [†]	-0.32 ± 0.35	-0.39 ± 0.50			0.39	<0.001
Functional ability score †	0.78 ± 0.50	0.39 ± 0.57			0.72	<0.001*
Number of incomplete tasks in 120 s [†]	-0.14 ± 0.79	-0.56 ± 0.93				
Grip strength, kg [†]	0.57 ± 3.2	0.51 ± 2.6			0.98	0.18
Weight to box, pounds †	2.4 ± 2.9	2.1 ± 2.5			0.83	<0.001
Six-minute walk test distance (meters) [†]	51.8 ± 45.9	16.3 ± 39.7	61.5 ± 56.5	20.2 ± 38.6	0.76	<0.001*
PeakVO ₂ (mL/kg/min) [†]	1.8 ± 2.2	0.23 ± 2.5			0.51	0.004*
		l			_	

EOT and EOT+4 presented as change from baseline (mean \pm SD) where † positive scores indicate improvement, or $^{\mp}$ negative scores indicate improvement.

Each row represents results from separate mixed-effect models including group and time (baseline, EOT, EOT+4).

Abbreviations: EOT, end of treatment; EOT + 4, 4 weeks following end of treatment; FE+RTP, forced-rate exercise plus repetitive task practice; RTP only, repetitive task practice only; UE, upper extremity; PeakVO₂, volume of oxygen consumption

^{*}Significant interaction effect between group and time, p<0.05

Table 3. Percentage of patients with change scores exceeding minimal clinically important difference

Change scores exceeding MCIDs at EOT	Total	FE+RTP	RTP only	Chi-square
Change scores exceeding MCDs at EO1	N (%)	N (%)	N (%)	P-value
Fugl-Meyer Assessment ≥4.25	41 (73.2)	22 (75.9)	19 (70.4)	0.64
Fugl-Meyer Assessment ≥7.25	22 (39.3)	14 (48.3)	8 (29.6)	0.15
Action Research Arm Test Total ≥5.7	19 (33.9)	12 (41.4)	7 (25.9)	0.22
Six-minute walk test ≥34.4	23 (42.6)	17 (60.7)	6 (23.1)	0.005
Change scores exceeding MCIDs at EOT+4*				
Fugl-Meyer Assessment ≥4.25	42 (77.8)	23 (82.1)	19 (73.1)	0.42
Fugl-Meyer Assessment ≥7.25	29 (53.7)	15 (53.6)	14 (53.9)	0.98
Action Research Arm Test Total ≥5.7	21 (39.6)	13 (48.2)	8 (30.8)	0.20
Six-minute walk test ≥34.4	21 (42.0)	15 (60.0)	6 (24.0)	0.010

^{*}Subset of patients with available change scores

Abbreviations: FE+RTP, forced-rate exercise plus repetitive task practice; RTP only, repetitive task practice only; MCID, minimal clinically important difference; EOT, end of treatment; EOT+4; 4 weeks following end of treatment





